Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | BCHE | P06276 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138125 | 1.00 | MAPT (0.63) | MAPTBCHECYP2C19CYP1B1ABCG2 | |
| SCHEMBL8987369 | 0.86 | PTGS1 (0.67) | MAPTBCHECYP2C19CYP1B1AR | |
| SCHEMBL8987373 | 0.86 | PTGS1 (0.67) | MAPTBCHECYP2C19CYP1B1AR | |
| SCHEMBL20608588 | 0.86 | MAOB (0.64) | MAPTCYP1B1MAOBMAOAMEN1 | |
| SCHEMBL5085506 | 0.86 | MAPT (0.64) | MAPTCYP1B1ABCG2MAOBMAOA | |
| SCHEMBL25510576 | 0.86 | P4HB (0.54) | MAPTCYP1B1MAOBMAOAMEN1 | |
| SCHEMBL5085503 | 0.86 | MAPT (0.64) | MAPTCYP1B1ABCG2MAOBMAOA | |
| SCHEMBL20608589 | 0.86 | MAOB (0.64) | MAPTCYP1B1MAOBMAOAMEN1 | |
| SCHEMBL27741821 | 0.85 | MAPT (0.60) | MAPTBCHECYP2C19CYP1B1AR | |
| SCHEMBL27579527 | 0.83 | MAPT (0.77) | MAPTBCHECYP2C19CYP1B1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007082178-A2 | PROSTAGLANDIN REDUCTASE INHIBITORS | ABGENOMICS CORPORATION (TW) | 2007-07-19 | — | — | WO | disclosed |
| EP-1803809-A2 | Modulation of peroxisome proliferator-activated receptors | Abgenomics Corporation (TW) | 2007-07-04 | — | — | EP | disclosed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | disclosed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MAPT 4566/4885BCHE 2050/4885CYP2C19 185/4885 |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | PPARG, PPARA, PPARD | MAPT 4229/4885BCHE 1840/4885CYP2C19 312/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | MAPT 4210/4885BCHE 948/4885CYP2C19 1629/4885 |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | PTGIR, PTGDR, PTGDR2 | MAPT 4718/4885BCHE 3207/4885CYP2C19 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.